Who is eligible?
Rare disease genomics labs, hereditary cancer labs, academic genomics groups, and variant review teams that can evaluate public, synthetic, or de-identified cases.
Governed genomic review intelligence, ready for controlled pilot evaluation.
Tynixa is prepared for controlled pilot access with selected labs using public, synthetic, or de-identified genomic cases only. Pilot access supports review-ready packages and human sign-off; it is not an autonomous clinical system.
Allowed data
Public cases, synthetic examples, and de-identified pilot cases. PHI, raw patient identifiers, and uncontrolled clinical release are not allowed in this stage.
What the lab receives
Review package examples, evidence-gap summaries, conflict notes, safety boundary reports, human-review routing, feedback cycles, and a pilot summary.
From briefing to commercial decision.
Lead → Pilot briefing → Qualification → Security review → Payment/assisted activation → Controlled pilot workspace → Review package evaluation → Feedback cycle → Pilot completion → Commercial decision.
Payment does not unlock clinical finalization.
Payment activates governed pilot workspace access only. Tynixa does not provide final diagnosis, final ACMG classification, treatment recommendations, PHI processing, or clinical release during controlled pilot access. Human review is required.
Controlled Pilot Access Plans
Early Access Pilot
$99 — introductory controlled pilot access.
Pay & Request AccessScientific Workflow Evaluation
$199 — workflow and review package evaluation.
Pay & Request EvaluationLab Pilot Access
$499 — lab-focused controlled pilot access.
Pay & Request Lab PilotUse one guided payment and account flow.
All paid pilot access starts from one page so Tynixa can create your account, pilot ID, checkout, and continuation link automatically.